high mobility group nucleosome binding domain 5Genealiases: NBP-45 · NSBP1
Q-omics provides the consensus-scored HMGN5 profile across patient tissues and cancer cell-line models. HMGN5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, HMGN5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HMGN5 RNA expression shows 19,003 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, KIRC, and UVM as cancer lineages where HMGN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN5 survival associations across molecular data types. HMGN5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN5 RNA expression–survival associations across cancer types. High HMGN5 expression shows unfavorable associations in UVM, but favorable associations in OV, LGG, PAAD, ACC and MESO. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for HMGN5 RNA expression.
This table summarizes HMGN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HMGN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN5 shows lower tumor expression in KIRC, THCA, BLCA, KICH, HNSC and LUSC. The KIRC box plot shows higher HMGN5 RNA expression in normal versus tumor tissue (log2 FC = −1.009, t-test p < 0.001).
This table shows molecular features associated with HMGN5 in patient tissues and cancer cell lines. In patient samples, HMGN5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HMGN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
